Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03449693|
Recruitment Status : Recruiting
First Posted : February 28, 2018
Last Update Posted : March 5, 2018
|Condition or disease||Intervention/treatment||Phase|
|Febrile Neutropenia||Dietary Supplement: Magnesium Oxide Supplement||Phase 2|
Febrile neutropenia (FN) is a worrying outcome in children receiving chemotherapy because it increments the risk of major complications, reduces quality of life and increments treatment costs. Moreover, it is the most common diagnosis in pediatric oncology patients that enter emergency rooms and the second most important cause of hospitalization, just behind hospitalization for administration of chemotherapy.
In Mexico, incidence of FN is of 62% of children with solid tumors treated with cisplatin-based chemotherapy (CBC). Cisplatin is one of the most nephrotoxic drugs being used in clinical settlements. The assessment of nephrotoxicity is made with the manifestation of tubular damage that causes electrolyte losses, specially of magnesium. Recently, our investigation group reported that there is an association of hypomagnesemia and the apparition of FN. This association has a biologic explanation in the fact that magnesium is a necessary cofactor for the neutrophil's diapedesis and the activation of complement cascade. To our knowledge, the role of magnesium supplementation has not been explored. With this evidence in mind, the investigators wondered if oral supplementation with magnesium will reduce FN episodes in pediatric oncology patients treated with CBC.
Objective: Determine the efficacy of oral supplementation with magnesium to reduce FN episodes in pediatric oncology patients treated with CBC.
Hypothesis: Previous clinical trials made in adult population have reported that supplementation with magnesium salts reduce episodes of hypomagnesemia in between 13 and 50%. Thus, oral supplementation with magnesium oxide will reduce 20% of FN episodes in pediatric oncology patients treated with CBC.
Materials and Methods: Randomized Clinical Trial, open-label, parallel groups of children over the age of nine with solid tumors treated with CBC at the Haemato-Oncology Department of the Hospital Infantil de México. To prove the hypothesis, it is required to randomize 107 CBC cycles to the intervention group and 107 CBC cycles to the control group. The sample size calculation was made by using the two proportions formula. Randomize of children will be made when they receive CBC indication. Patients assigned to the intervention group will receive institutional attention protocol plus a bottle of magnesium oxide, at the moment of hospitalization discharge. Patients assigned to the control group will receive only institutional attention protocol. The follow-up of patients will be made until an episode of FN appears or until the patient comes back for another CBC cycle. FN assessment will be measured with a unique temperature >38.3°C or a sustained temperature >38°C over the course of an hour plus a count of neutrophils under 1000 cells/mm3. The efficacy of oral supplementation with magnesium oxide will be determined by a Relative Risks calculation with confidence interval of 95% (CI95%). Moreover, Absolute Risk Reduction will be calculated, as well as Necessary Number to Treat. To adjust the principal variable a multivariate analysis will be made with a multiple logistic regression. The analysis will be made by protocol and by intention to treat.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||214 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Two groups: Intervention group and control group. The intervention group will receive institutional care protocol plus oral supplementation with magnesium. The control group will receive institutional care protocol only.|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia in Pediatric Oncology Patients Treated With Cisplatin-Based Chemotherapy: Randomized Clinical Trial|
|Actual Study Start Date :||October 19, 2017|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
Experimental: Magnesium Oxide Supplement
Magnesium Oxide 250 mg tablet, daily for 30 days.
Dietary Supplement: Magnesium Oxide Supplement
Magnesium Oxide tablet
Other Name: M250
No Intervention: No Supplement
- Febrile Neutropenia [ Time Frame: After randomization until day 30 ]Unique temperature >38.3°C or sustained temperature >38°C over the course of an hour, and a total count of neutrophils <1000 cells/mm3.
- Time passed from cisplatin-based chemotherapy until the apparition of febrile neutropenia [ Time Frame: After randomization until day 30 ]Total of days passed from the randomization up to the apparition of febrile neutropenia
- Safety of Oral Supplementation with Magnesium [ Time Frame: Evaluate the apparition of adverse effects of oral supplement of magnesium oxide Time Frame: After randomization until day 30 ]Evaluate the apparition of adverse effects of oral supplement of magnesium oxide
- Hypomagnesemia [ Time Frame: After randomization until day 30 ]Serum magnesium <1.6 mg/mL
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03449693
|Contact: Victoria E Barrios, QFB||+52 1 email@example.com|
|Hospital Infantil de Mexico Dr. Federico Gomez||Recruiting|
|Cuauhtémoc, Ciudad De México, Mexico, 06720|
|Contact: Victoria E Barrios, QFB +52 1 2291290208 firstname.lastname@example.org|
|Contact: Miguel A Palomo, MD|
|Principal Investigator:||Osvaldo D Castelán, PhD||Universidad Nacional Autónoma de México. Facultad de Estudios Superiores Zaragoza|
|Principal Investigator:||Miguel A Palomo, PhD||Hospital Infantil de México Dr. Federico Gómez|